NovoCure Limited Company Profile (NASDAQ:NVCR)

About NovoCure Limited

NovoCure Limited logoNovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death. A TTFields delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories. The electric fields are delivered through the non-invasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The therapy is designed to be delivered throughout the day and night. The Company has performed various pre-clinical research on TTFields and their effects in multiple solid tumor cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NVCR
  • CUSIP:
Key Metrics:
  • Previous Close: $7.70
  • 50 Day Moving Average: $7.13
  • 200 Day Moving Average: $7.91
  • 52-Week Range: $5.95 - $18.72
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.38
  • P/E Growth: -0.08
  • Market Cap: $668.21M
  • Outstanding Shares: 86,780,000
  • Beta: 4.17
Profitability:
  • Net Margins: -219.29%
  • Return on Equity: -69.89%
  • Return on Assets: -50.57%
Debt:
  • Debt-to-Equity Ratio: 0.61%
  • Current Ratio: 9.14%
  • Quick Ratio: 8.33%
Additional Links:
Companies Related to NovoCure Limited:

Analyst Ratings

Consensus Ratings for NovoCure Limited (NASDAQ:NVCR) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $18.60 (141.56% upside)

Analysts' Ratings History for NovoCure Limited (NASDAQ:NVCR)
Show:
DateFirmActionRatingPrice TargetDetails
1/11/2017Wells Fargo & CompanyDowngradeOutperform -> Market PerformView Rating Details
1/11/2017WedbushReiterated RatingOutperform$20.00View Rating Details
11/2/2016J P Morgan Chase & CoSet Price TargetBuy$14.00View Rating Details
7/29/2016JMP SecuritiesLower Price TargetMarket Outperform$43.00 -> $34.00View Rating Details
7/29/2016Deutsche Bank AGLower Price TargetHold$28.00 -> $16.00View Rating Details
7/29/2016Barclays PLCLower Price TargetUnderweight$12.00 -> $9.00View Rating Details
11/12/2015Evercore ISIInitiated CoverageBuy$29.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for NovoCure Limited (NASDAQ:NVCR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017        
11/2/2016($0.42)($0.39)ViewN/AView Earnings Details
7/28/2016Q216($0.37)($0.48)$15.90 million$17.90 millionViewListenView Earnings Details
5/9/2016Q116($0.33)($0.42)$23.65 million$13.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NovoCure Limited (NASDAQ:NVCR)
Current Year EPS Consensus Estimate: $-1.62 EPS
Next Year EPS Consensus Estimate: $-1.43 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.32)($0.31)($0.32)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.43)($0.43)($0.43)
Q4 20161($0.44)($0.44)($0.44)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NovoCure Limited (NASDAQ:NVCR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for NovoCure Limited (NASDAQ:NVCR)
Insider Ownership Percentage: 33.90%
Institutional Ownership Percentage: 21.98%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/22/2016Michael J AmbrogiCOOSell27,500$8.27$227,425.00View SEC Filing  
12/20/2016Michael J AmbrogiCOOSell20,000$8.62$172,400.00View SEC Filing  
12/19/2016Michael J AmbrogiCOOSell20,000$8.76$175,200.00View SEC Filing  
12/16/2016Michael J AmbrogiCOOSell40,000$8.93$357,200.00View SEC Filing  
12/14/2016Michael J AmbrogiCOOSell40,000$8.97$358,800.00View SEC Filing  
12/12/2016Michael J AmbrogiCOOSell15,000$9.01$135,150.00View SEC Filing  
12/8/2016Michael J AmbrogiCOOSell10,000$8.30$83,000.00View SEC Filing  
12/6/2016Michael J AmbrogiCOOSell10,000$8.24$82,400.00View SEC Filing  
8/5/2016Gert L PerlhagenDirectorSell676,576$1.85$1,251,665.60View SEC Filing  
6/8/2016Michael J AmbrogiCOOSell20,000$12.24$244,800.00View SEC Filing  
3/3/2016Asaf DanzigerCEOBuy10,000$15.00$150,000.00View SEC Filing  
3/3/2016Robert J Mylod JrDirectorBuy20,000$15.78$315,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for NovoCure Limited (NASDAQ:NVCR)
DateHeadline
capitalcube.com logoNovocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : February 17, 2017 (NASDAQ:NVCR)
us.rd.yahoo.com - February 18 at 11:52 AM
News IconAre Analysts Optimistic About Where Novocure Ltd (NASDAQ:NVCR) is Heading? - Winfield Review (NASDAQ:NVCR)
winfieldreview.com - February 17 at 4:36 PM
News IconActive Trading Watch on Shares of Novocure Ltd (NVCR) - BVN (NASDAQ:NVCR)
bvnewsjournal.com - February 17 at 8:21 AM
uk.finance.yahoo.com logoFirst Patient Enrolled in Novocure’s Phase 3 Pivotal LUNAR Trial Testing Tumor Treating Fields for the Treatment of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy (NASDAQ:NVCR)
uk.finance.yahoo.com - February 16 at 6:29 PM
nasdaq.com logoNotable Tuesday Option Activity: NVCR, WYNN, GM (NASDAQ:NVCR)
www.nasdaq.com - February 14 at 10:06 PM
News IconStock Update: Checking the Technicals for Novocure Ltd (NVCR) - Sherwood Daily (NASDAQ:NVCR)
sherwooddaily.com - February 11 at 1:06 AM
uk.finance.yahoo.com logoNovocure to Participate in the BIO 2017 CEO & Investor Conference (NASDAQ:NVCR)
uk.finance.yahoo.com - February 7 at 9:16 AM
News IconWhat’s Propelling Novocure Ltd (NVCR) to Decrease? The Stock Formed a Double Bottom Chart Pattern (NASDAQ:NVCR)
randolphguide.com - February 2 at 7:50 PM
News IconNovocure Ltd (NASDAQ:NVCR) Investor Investigation over possible Violations of Securities Laws (NASDAQ:NVCR)
satprnews.com - January 26 at 3:06 AM
News IconTrading Radar: Zooming in on Shares of Novocure Ltd (NVCR) - Sherwood Daily (NASDAQ:NVCR)
sherwooddaily.com - January 25 at 5:45 AM
uk.finance.yahoo.com logoNovocure to Participate in Noble Capital Markets’ 13th Annual Investor Conference (NASDAQ:NVCR)
uk.finance.yahoo.com - January 24 at 8:45 AM
News IconCCI Level Check for Novocure Ltd (NVCR) - Sherwood Daily (NASDAQ:NVCR)
sherwooddaily.com - January 22 at 6:45 PM
finance.yahoo.com logoJohnson & Weaver, LLP Initiates Investigations of Rent-A-Center, Inc., KalVista Pharmaceuticals, Inc., NovoCure Limited and Inotek Pharmaceuticals Corp. (NASDAQ:NVCR)
finance.yahoo.com - January 21 at 12:44 AM
News IconWhat are the Levels Indicating for This Stock: Novocure Ltd (NVCR) - Sherwood Daily (NASDAQ:NVCR)
sherwooddaily.com - January 20 at 7:43 PM
News IconEarnings According to Analysts for Novocure Ltd (NASDAQ:NVCR)? - Aiken Advocate (NASDAQ:NVCR)
aikenadvocate.com - January 20 at 7:43 PM
News IconLooking at Moving Averages for Novocure Ltd (NVCR) - Rives Journal (NASDAQ:NVCR)
rivesjournal.com - January 20 at 7:43 PM
News IconNovocure Ltd. (Nasdaq: NVCR) Releases Big Announcement - StockNewsUnion (NASDAQ:NVCR)
stocknewsunion.com - January 20 at 7:43 PM
4-traders.com logoNovocure :’s Optune® Now Available at 500 Cancer Treatment Centers in the U.S. (NASDAQ:NVCR)
www.4-traders.com - January 19 at 11:27 PM
uk.finance.yahoo.com logoNovocure’s Optune® Now Available at 500 Cancer Treatment Centers in the U.S. (NASDAQ:NVCR)
us.rd.yahoo.com - January 19 at 11:27 PM
News IconWells Fargo Downgrades Novocure Ltd to Market Perform - Highland Mirror (NASDAQ:NVCR)
www.highlandmirror.com - January 19 at 5:35 AM
News IconRating Sentiment Change: How Analysts Rated Novocure Ltd (NASDAQ:NVCR) Last Week? - Fair View Times (NASDAQ:NVCR)
fairviewtimes.com - January 19 at 5:35 AM
News IconWill The Needle Move For Novocure Ltd (NASDAQ:NVCR) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:NVCR)
wsbeacon.com - January 13 at 5:36 AM
barrons.com logo[$$] Novocure's Disappointing Trend (NASDAQ:NVCR)
www.barrons.com - January 12 at 7:33 PM
us.rd.yahoo.com logoNovocure Announces Preliminary Fourth Quarter and Full Year 2016 Operating Statistics (NASDAQ:NVCR)
us.rd.yahoo.com - January 10 at 7:49 PM
finance.yahoo.com logo7:01 am NovoCure reports prelim Q4 results; 1,091 active patients at Dec. 31, 2016, an increase of 80% Y/Y (NASDAQ:NVCR)
finance.yahoo.com - January 10 at 7:49 PM
uk.finance.yahoo.com logoNovocure to Report Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:NVCR)
uk.finance.yahoo.com - January 10 at 8:47 AM
News IconInvestigation for Investors in Shares of Novocure Ltd (NVCR) Announced (NASDAQ:NVCR)
www.digitaljournal.com - January 5 at 10:37 PM
capitalcube.com logoNovocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : January 5, 2017 (NASDAQ:NVCR)
www.capitalcube.com - January 5 at 10:37 PM
capitalcube.com logoETFs with exposure to Novocure Ltd. : January 3, 2017 (NASDAQ:NVCR)
www.capitalcube.com - January 3 at 5:12 PM
News IconGrowth Story Unfolding for NovoCure Limited (NASDAQ:NVCR) - Prospect Journal (NASDAQ:NVCR)
prospectjournal.com - January 3 at 10:32 AM
4-traders.com logoNovoCure Limited (NASDAQ:NVCR) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:NVCR)
www.4-traders.com - December 30 at 7:17 PM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces an Investigation of NovoCure Limited, and Advises Investors with Losses to Contact the Firm (NASDAQ:NVCR)
finance.yahoo.com - December 28 at 9:58 AM
capitalcube.com logoNovocure Ltd. – Value Analysis (NASDAQ:NVCR) : December 27, 2016 (NASDAQ:NVCR)
www.capitalcube.com - December 27 at 6:48 PM
finance.yahoo.com logoINVESTOR ALERT: Investigation of NovoCure Limited Announced by The Wagner Firm (NASDAQ:NVCR)
finance.yahoo.com - December 27 at 6:48 PM
capitalcube.com logoNovocure Ltd. breached its 50 day moving average in a Bearish Manner : NVCR-US : December 26, 2016 (NASDAQ:NVCR)
www.capitalcube.com - December 26 at 9:52 AM
marketexclusive.com logoInsider Trading Activity NovoCure Ltd. (NASDAQ:NVCR) – COO Sold 27,500 shares of Stock (NASDAQ:NVCR)
marketexclusive.com - December 23 at 7:06 PM
News IconIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Novocure Limited. & Encourages Investors to Cont... (NASDAQ:NVCR)
ih.advfn.com - December 22 at 7:14 PM
finance.yahoo.com logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of NovoCure Limited Investors (NASDAQ:NVCR)
finance.yahoo.com - December 22 at 7:14 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Novocure Limited. and Encourages Investors to Contact the Firm (NASDAQ:NVCR)
finance.yahoo.com - December 22 at 7:14 PM
News IconIMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Novocure Limited. & Advises Investors with Losses to ... (NASDAQ:NVCR)
ih.advfn.com - December 22 at 7:41 AM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Novocure Limited. and Advises Investors with Losses to Contact the Firm (NASDAQ:NVCR)
finance.yahoo.com - December 22 at 7:41 AM
4-traders.com logoBronstein, Gewirtz & Grossman, LLC Announces Investigation of NovoCure Limited (NVCR) (NASDAQ:NVCR)
www.4-traders.com - December 21 at 7:45 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of NovoCure Limited (NVCR) (NASDAQ:NVCR)
finance.yahoo.com - December 21 at 7:45 PM
finance.yahoo.com logoGlancy Prongay & Murray LLP Commences Investigation on Behalf of NovoCure Limited Investors (NASDAQ:NVCR)
finance.yahoo.com - December 21 at 7:45 PM
News IconMeasuring the Levels on Shares of Novocure Ltd (NVCR) - Yankee Analysts (NASDAQ:NVCR)
yankeeanalysts.com - December 20 at 11:52 PM
News IconIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Novocure Limited, & Advises Investors with Losses to... (NASDAQ:NVCR)
ih.advfn.com - December 20 at 6:08 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Novocure Limited, and Advises Investors with Losses to Contact the Firm (NASDAQ:NVCR)
finance.yahoo.com - December 20 at 6:08 PM
News IconMonitoring Relative Strength Index Values for Novocure Ltd (NVCR) - Yankee Analysts (NASDAQ:NVCR)
yankeeanalysts.com - December 20 at 1:06 PM
4-traders.com logoNovocure :’s Optune® (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblastoma (NASDAQ:NVCR)
www.4-traders.com - December 19 at 9:17 AM
publicnow.com logoNovocure’s Optune® (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblastoma (NASDAQ:NVCR)
www.publicnow.com - December 19 at 9:17 AM

Social

What is NovoCure Limited's stock symbol?

NovoCure Limited trades on the NASDAQ under the ticker symbol "NVCR."

Where is NovoCure Limited's stock going? Where will NovoCure Limited's stock price be in 2017?

6 brokers have issued 12-month target prices for NovoCure Limited's shares. Their predictions range from $9.00 to $34.00. On average, they expect NovoCure Limited's share price to reach $18.60 in the next twelve months.

When will NovoCure Limited announce their earnings?

NovoCure Limited is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about NovoCure Limited stock?

Here are some recent quotes from research analysts about NovoCure Limited stock:

  • According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (1/11/2017)

  • J P Morgan Chase & Co analysts commented, "Novocure reported 4Q15 top-line results in-line with the commercial metrics that were pre-announced at The J.P. Morgan Healthcare Conference. Our biggest takeaway from the print and call is the ongoing progress NVCR has made thus far with Optune’s launch into newly diagnosed GBM. We had an opportunity to catch up with NVCR after the call and, while they didn’t provide guidance because of the current complexities of accounting methods, they appeared comfortable with current Street expectations. Overall, we continue to see Optune’s launch as the most crucial aspect to the NVCR story and will be closely watching its progress over the coming quarters." (3/1/2016)

Who owns NovoCure Limited stock?

NovoCure Limited's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (5.63%), State Street Corp (0.99%), Federated Investors Inc. PA (0.06%), State Board of Administration of Florida Retirement System (0.02%) and Flinton Capital Management LLC (0.02%). Company insiders that own NovoCure Limited stock include Asaf Danziger, Gert L Perlhagen, Michael J Ambrogi and Robert J Mylod Jr.

Who sold NovoCure Limited stock? Who is selling NovoCure Limited stock?

NovoCure Limited's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp. Company insiders that have sold NovoCure Limited stock in the last year include Gert L Perlhagen and Michael J Ambrogi.

Who bought NovoCure Limited stock? Who is buying NovoCure Limited stock?

NovoCure Limited's stock was acquired by a variety of institutional investors in the last quarter, including Flinton Capital Management LLC and FMR LLC. Company insiders that have bought NovoCure Limited stock in the last two years include Asaf Danziger and Robert J Mylod Jr.

How do I buy NovoCure Limited stock?

Shares of NovoCure Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of NovoCure Limited stock cost?

One share of NovoCure Limited stock can currently be purchased for approximately $7.70.

NovoCure Limited (NASDAQ:NVCR) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for NovoCure Limited (NASDAQ:NVCR)

Earnings History Chart

Earnings by Quarter for NovoCure Limited (NASDAQ:NVCR)

Dividend History Chart

Dividend Payments by Quarter for NovoCure Limited (NASDAQ:NVCR)

Last Updated on 2/20/2017 by MarketBeat.com Staff